By incorporating a gene-suppressing drug into an over-the-counter gel, researchers at Albert Einstein College of Medicine and their colleagues cut healing time by half and significantly improved healing outcomes compared to control treatments.
Results from the combination therapy, which was tested in mice, were published online today in Advances in Wound Care,
“Not only did wound healing occur more rapidly and completely, but actual regeneration occurred, with hair follicles and the skin’s supportive collagen network restored in wounded skin—clinically important improvements that are unprecedented in wound care,” says senior author David J. Sharp, Ph.D., professor of physiology & biophysics at Einstein. “We foresee this therapy having broad application for all sorts of wounds, from playground cuts to battlefield injuries to chronic wounds.”
Chronic wounds alone affect 6.5 million Americans and cost $25 billion in annual healthcare costs. Over the past several decades, few advances have been made in treating wounds of any type.
In 2015, Dr. Sharp and colleagues discovered that an enzyme called fidgetin-like 2 (FL2) puts the brakes on skin cells as they migrate towards wounds to heal them. He reasoned that reducing FL2 levels might enable healing cells to reach their destination faster. So he and his colleagues developed small interfering RNA molecules (siRNAs) that specifically inhibit the gene that codes for FL2. When the siRNAs were encased in nanoparticles and sprayed on skin wounds in mice, the treated wounds healed faster than untreated wounds.
In the current study, Dr. Sharp enhanced the siRNAs’ wound-healing potential by combining them with PluroGel—a protective gel that keeps wounds moist and has antimicrobial properties when applied to bandages and other wound dressings. In addition, Dr. Sharp incorporated the siRNAs into microparticles made of collagen, a naturally occurring protein that readily releases its siRNA “cargo” after coming in contact with the skin.
The FL2-siRNA/PluroGel combination was applied to mice with either skin excisions or burns. For comparison, studies involving both types of skin injuries also used two control groups: mice treated with PluroGel alone and mice treated with PluroGel plus siRNA that did not target the gene for FL2. Wounds were treated on the day of the skin excision or burn and again two, four and six days later. For 14 days following the injuries, wounds were assessed by investigators who were “blinded” as to the treatment the mice received.
On the fourth day after mice treated for excision wounds, the open wound areas of mice in the two control groups were nearly twice as large as the wound areas in mice treated with the FL2-siRNA/PluroGel combination. Several mice treated with the combination therapy also had hair follicles present in the wound zone, while no such structures were seen in the control mice.
For mice treated for burns: by 14-days post injury, the wounds of mice in both control groups were more than one-third larger than in the mice treated with the FL2-siRNA/PluroGel combination. In addition, the burn wounds of all mice treated with the FL2-siRNA/PluroGel combination had closed completely by day 14; by comparison, 25 percent and 30 percent of treated wounds in the PluroGel and PluroGel/nontarget siRNA control groups, respectively, remained unhealed at that time.
“These results show that FL2-siRNA plus PluroGel is a highly promising wound treatment,” says Adam Kramer, a Ph.D. candidate in Dr. Sharp’s lab and co-lead author. “By lowering FL2 levels in skin cells, the FL2-siRNA helps cells reach wound sites much faster than they ordinarily would—essential for minimizing scarring and preventing wounds from becoming chronic. And by hydrating wounds and inhibiting microbes, PluroGel offers important additional wound-healing benefits.”
Dr. Sharp and Brian O’Rourke, Ph.D., the paper’s co-lead author and chief scientist at MicroCures, Inc., have achieved similar success in treating skin wounds in pigs—animals with skin that closely resembles human skin. Dr. Sharp’s team plans to seek permission from the U.S. Food and Drug Administration to test their wound-healing therapy in clinical trials.
Learn more: Novel Combination Therapy Promotes Wound Healing
The Latest on: Combination therapy
via Google News
The Latest on: Combination therapy
- Support for abatacept–methotrexate combination therapy in RA patients on December 14, 2018 at 3:00 am
medwireNews: Adding abatacept to methotrexate improves disease activity and reduces structural progression among anticitrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA) patients w... […]
- Global Combination Therapy Drug Market Supply, Sales, Revenue and Forecast from 2018 to 2025 on December 14, 2018 at 12:31 am
Global Combination Therapy Drug Market by Manufacturers, Types, Regions and Application Research Report Forecast to 2025 (EMAILWIRE.COM, December 14, 2018 ) Global Combination Therapy Drug Market repo... […]
- Novartis International AG - Novartis data demonstrates consistent efficacy and ... on December 8, 2018 at 6:11 am
Novartis International AG / Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visc... […]
- Combination Therapy May Improve Anticoagulant Activity, Reduce Hypertensive Organ Damage on December 8, 2018 at 5:47 am
CHICAGO —A combination of anticoagulation and antihypertensive therapies may be more effective than individual agents alone for improving overall coagulant activity and reducing hypertensive organ dam... […]
- Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast... on December 8, 2018 at 5:27 am
EAST HANOVER, N.J., Dec. 8, 2018 /PRNewswire/ -- Novartis today announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali ® (ribociclib) plus endocrine ... […]
- Novartis data demonstrates consistent efficacy... on December 8, 2018 at 4:02 am
. Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plu... […]
- Metastatic Prostate Cancer Target Identified for Combo Therapy on December 6, 2018 at 6:33 am
Studies in genetically engineered mouse models (GEMM) and data from human prostate cancer patients indicate that administering drugs targeting the histone methyltransferase nuclear receptor binding SE... […]
- Selecting Second-Line Therapy for Metastatic RCC on December 5, 2018 at 6:57 am
If patients have a VEGF therapy upfront, either monotherapy or in combination, they’re also going to go on to a VEGF therapy. Right now, even though we’re adding agents and shuffling how we approach p... […]
- Adult T-Cell Leukemia-Lymphoma Therapeutics: IFN-alpha, Zidovudine Combination Drug Therapy Upticks Survival Rate on December 5, 2018 at 12:17 am
Triggered by HTLV-1 virus, adult T-cell leukemia/lymphoma is a rare cancer of the T-cells in immune system. Prevailing therapeutics is limited to treatment of the cancer with no apparent inhibiting fa... […]
via Bing News